Clinical Trial Update: A Rollover Protocol for Subjects Previously Treated With AGS-003 [Phase 2]

View source ↗

Summary

This clinical trial update notes a rollover protocol for previously treated subjects in a Phase 2 study of AGS-003 for renal cell carcinoma, with the study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AGS-003 (RNA-loaded autologous dendritic cell vaccine)

Snippet

Sponsor: Argos Therapeutics | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED